Crossmark

Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study

Crossref DOI link: https://doi.org/10.1007/s00228-023-03479-3

Published Online: 2023-03-24

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Trkulja, Vladimir https://orcid.org/0000-0002-0968-1194
Kodvanj, Ivan https://orcid.org/0000-0002-1359-3701
Funding

Funding for this research was provided by:

Medicinski Fakultet, Sveučilište u Zagrebu (no grant id, no grant id)
License Information

Text and Data Mining valid from 2023-03-24

Version of Record valid from 2023-03-24
More Information

Article History

Received: 5 November 2022

Accepted: 14 March 2023

First Online: 24 March 2023

Declarations

:

: This study used anonymized administrative data standardly collected on routine procedures, hence ethical approval was waived by the Ethics Committee of the Zagreb University School of Medicine and Croatian Institute for Public Healthy.

: The authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below